Clinicopathologic Factors Affecting Recurrence after Curative Surgery for Stage I Colorectal Cancer

Min Ae Keum; Seok-Byung Lim; Sun A Kim; Yong Sik Yoon; Chan Wook Kim; Chang Sik Yu; Jin Cheon Kim

doi:10.3393/jksc.2012.28.1.49

Articles

Page Path: HOME > J Korean Soc Coloproctol > Volume 28(1); 2012 > Article

Original Article Clinicopathologic Factors Affecting Recurrence after Curative Surgery for Stage I Colorectal Cancer: Min Ae Keum, Seok-Byung Lim, Sun A Kim¹, Yong Sik Yoon, Chan Wook Kim, Chang Sik Yu, Jin Cheon Kim; Journal of the Korean Society of Coloproctology 2012;28(1):49-55.
DOI: https://doi.org/10.3393/jksc.2012.28.1.49
Published online: February 29, 2012

Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

¹Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Correspondence to: Jin Cheon Kim, M.D. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3489, Fax: +82-2-3010-6701, jckim@amc.seoul.kr

• Received: August 31, 2011 • Revised: October 19, 2011 • Accepted: November 16, 2011

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,953 Views
52 Download
35 Crossref
34 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ARTICLE INFORMATION
REFERENCES

Abstract

Purpose
The objective of the current study was to identify the clinicopathological risk factors affecting recurrence after a curative resection for stage I colorectal cancer.
Methods
We retrospectively studied 434 patients who underwent a curative resection for stage I colorectal cancer between January 1999 and December 2004. Postoperative oral chemotherapy was performed in 189 patients (45.3%). The following prognostic factors were correlated with recurrence: age, gender, preoperative carcinoembryonic antigen level, location of tumor, T stage, size of tumor, histologic differentiation, growth pattern, and lymphovascular invasion. The median follow-up duration was 65 months.
Results
The overall recurrence rate was 4.6% (20/434). The median time to recurrence was 33 months. Two-thirds of the recurrence occurred more than two years after surgery. Risk factors associated with recurrence were rectal cancer (P = 0.009), T2 stage (P = 0.010), and infiltrative growth pattern (P = 0.020). A Cox proportional hazards regression analysis demonstrated that the infiltrative growth pattern was an independent predictor for recurrence. Tumor cell budding was observed in all pathologic reviews with recurrence.
Conclusion
Long-term follow-up is necessary for stage I colorectal patients with high risk factors like rectal cancer, T2 stage, and infiltrative growth pattern.
Keywords: Colorectal neoplasms; Recurrence; Risk factors

INTRODUCTION

Colorectal cancer is the third most prevalent cancer in South Korea, following gastric cancer and thyroid cancer. It accounts for 12.7% of all cancers, and its prevalence is increasing [1]. Because the number of early diagnoses of the stage I colorectal cancer is tending to increase as the number of people being screened with occult blood tests and colonoscopy through the national campaign for cancer screening has increased [2], an excellent prognosis of greater than 90% 5-year survival post radical resection is being achieved [3]. Although 10 to 13% of stage I colorectal cancer patients who undergo a radical resection experience recurrence, adjuvant chemotherapy is generally not recommended for them because it does not improve their survival rate [4, 5]. The purpose of this study is to select clinicopathologic factors related to the recurrence among stage I colorectal cancer patients who undergo a radical resection.

METHODS

Among the 4.489 patients who had radical resections due to colorectal carcinomas in this Department of Colorectal Surgery between January 1999 and December 2004, 515 patients (11.4%) were diagnosed with first-stage colorectal cancer on histopathologic examination. A radical resection is defined as a surgical resection that ligates the origin of feeding vessels and takes all lymph nodes between the pericolic lymph nodes and the principle lymph nodes. Among these 515 patients, familial adenomatous polyposis (21 patients), hereditary non-polyposis colorectal cancer (14 patients) and patients who had preoperative chemoradiation therapy (46 patients) were excluded, and finally 434 patients were chosen as subjects for this study. Retrospective analyses of clinicopathologic factors and of follow-up test results were conducted with prospectively collected data. Among the 434 subjects, 189 had postoperative oral immunochemotherapy. The surgeons decided on this for patients carrying a high risk of recurrence as they presented with evidence of lymphovascular invasion or T2 stage, poorly differentiated cancer, and signet ring cell carcinomas during the surgery and on the pathologic diagnosis. Single oral chemotherapy (tegafur/uracil or doxifluridine) or one combined with an immune modulator (polysaccharide-k) therapy was administered for at least 3 months up to 12 months; 113 patients among 189 patients had the combined therapy.

All the subjects were categorized into the recurrence group and the non-recurrence group during the follow-up period, and their clinicopathologic factors (age, sex, preoperative carcinoembryonic antigen value, the location of tumor T stage [T1 or T2], the size of tumors, the gross finding of the tumor [fungating type or infiltrative type], histologic grade, lymphovascular invasion, the number of obtained lymph nodes, postoperative oral immunochemotherapy) were compared and analyzed. The diagnosis of recurrence was completed by radiological or histological investigation, and the time to recurrence was counted from the operation day. Local recurrence was defined as occurring when the cancer was recurrent in the anastomosis site or in the structure of the pelvic cavity (vagina, bladder, and lymph nodes located in the pelvic cavity), and distant recurrence was defined as occurring when the cancer was recurrent in the systemic lymph nodes, liver, lung, peritoneum, bones and brain [6]. The mean period of follow-up of all the patients was 65 months (2 to 127 months). An independent-sample t-test for continuous variables and a chi-square test for nominal variables were conducted. A multivariate analysis was conducted for clinicopathologic factors that were judged to be statistically significant through a Kaplan-Meier survival analysis, and the Cox regression model was used for the analysis. Results were judged to be statistically significant when P-value was less than 0.05 bilaterally.

RESULTS

Table 1 summarized the clinicopathologic characteristics of the 434 patients who were diagnosed with stage I colorectal cancer after a radical resection due to a sporadic colorectal carcinoma. Recurrence was identified in 20 (4.6%) patients during the follow-up period, and they were classified as the recurrence group. The median value of the time to recurrence was 33 months (range, 3 to 71 months). The invasion depth of the recurrent T1 stage patients was sm3. Among the 20 patients experiencing recurrence, 5 had a reoperation and chemotherapy, 8 had chemotherapy and radiotherapy, and 7 had only symptom-control treatments. Of the 20, 14 expired during the follow-up period. The mean survival period of the remaining 6 patients was 39 months (range, 14 to 68 months) after the above treatments for recurrence, and only 2 patients among the 6 survived longer than 5 years. Table 2 presents the clinicopathologic findings, the location of recurrence, the treatments, and the progress of the disease for the recurrence group.

Table 3 presents a comparative analysis of the clinicopathologic findings for the recurrence group and for the non-recurrence group. The location of the tumor (P = 0.009), T stage (P = 0.010) and gross finding (P = 0.017) were found to be significant in the univariate analysis of the clinicopathologic factors affecting recurrence. A multivariate analysis was conducted on the clinicopathologic factors found to be significant in the univariate analysis, and the gross finding of the tumor (P = 0.020) was identified as an independent factor affecting recurrence. Table 4 presents the postoperative oral immunochemotherapy and clinicopathologic findings for the recurrence group and the non-recurrence group. It shows that postoperative oral immunochemotherapy had no statistically significance relation to recurrence. The pathology slides of the patients experiencing recurrence were analyzed again by another pathologist for the presence of tumor cell budding, which was found in all the patients experiencing recurrence (Fig. 1).

DISCUSSION

The overall prognosis for stage I colorectal cancer shows an excellent outcome of greater than 90% for the 5-year survival rate [3], but 10 to 13% of the patients still experience recurrence [7-10]. T2 stage tumor [8-10], lymphovascular invasion [7, 8], lower rectal lesions [9], male sex [7], a poorly-differentiated carcinoma [7] and high preoperative carcinoembryonic antigen value [10] were identified as influential factors related to the recurrence of stage I colorectal cancer in previous studies. Table 5 summarizes the results of previous studies related to the recurrence of first-stage colorectal cancer and compares them with the results of this study.

In this study, infiltrative type on the gross finding was identified as an independent factor affecting the recurrence in stage I colorectal cancer. An infiltrative type of colorectal cancer has been reported to have a significant effect on recurrence because it invades the pericolorectal fatty tissues and lymph nodes more rapidly than the fungating type [11-13]. Steinberg et al. [11] reported that among influential factors affecting the prognosis of colon cancer after surgical interventions, the relative risk was 0.52 (P = 0.004) when a fungating type of colorectal cancer existed on the gross finding. Manfredi et al. [12] reported that the relative risk of an infiltrative type of colorectal cancer was 1.2 times greater (P = 0.037) than that of a fungating type of colorectal cancer when it comes to distant recurrence.

The presence of tumor cell budding was found in the pathology slides of all 20 patients experiencing recurrence in this study. Tumor cell budding is known to be related to metastasis to lymph nodes [14, 15] and lymphovascular invasion [16] in cases of a submucosal invasive colorectal carcinoma. Hase et al. [17] analyzed the prognosis of colorectal cancer for 663 patients having had a radical resection after classifying the grade of tumor cell budding into two groups and concluded that tumor cell budding was a powerful prognostic factor because a significant difference in recurrence rates (71.1% vs. 22.2%, P < 0.005) and in 10-year survival rates (50.6% vs. 13.8%, P < 0.001) existed. Ueno et al. [18] established their own criterion, named high-grade budding (>10 foci within a microscopic field of x250), and reported that high-grade budding was related to aggressive characteristics such as histological grade, proper muscle invasion, lymph-node metastasis, growth patterns and vascular invasion. Classifying the grade of tumor cell budding of the patients experiencing recurrence in this study, highgrade budding (as it was defined by Ueno et al.) was observed in 8 cases (40%). Although the presence of tumor cell budding or high-grade budding was not found to be an influential factor affecting the recurrence of the stage I colorectal cancer because the result of tumor cell budding of the non-recurrence group was not confirmed in this study, further studies regarding tumor cell budding are thought to be required because the finding of tumor cell budding is judged to be related to the growth patterns and the histological grade of the tumor.

When a univariate analysis for the characteristics of recurrence according to the location of the primary tumor, rectal cancer showed a higher recurrence rate than colon cancer (6.6% vs. 1.4%, P = 0.009). Although no significant difference between the recurrence rate at the upper rectum and at the lower rectum in rectal cancer was noted, 17 cases (90%) among 19 cases of recurrent rectal cancer were located in the middle and in the lower rectum, indicating the characteristics of recurrence were different between the two locations. T stage tumors are known to be an independent factor related to the recurrence of colorectal cancer, and T2 stage identified in stage I colorectal cancer patients has been reported to be an independent factor related to recurrence [10, 13, 19, 20]. In this study, T2 stage was not identified as a significant influential factor related to recurrence (P = 0.064). The reason for this is thought to be the number of the patients, and a more significant result should be gained with bigger samples in further studies. Male sex and lymphovascular invasion were also identified as risk factors related to recurrence of stage I colorectal cancer in previous studies, although significant statistical results were not obtained in this study. Male sex has been understood as a poor prognostic factor for a long time, and in recent years, it has been recognized more as an independent poor prognostic factor in stage II and III rectal cancer [21]. Lymphovascular invasions have been reported as a poor prognostic factor in colorectal cancer patients [22, 23]. The authors reported that the recurrence rate was significantly higher when lymphovascular invasion was identified in sporadic colorectal cancer. Also, especially in recent studies, recurrence in systemic lymph nodes was significant [24]. About 80% of the recurrences after a radical resection in colorectal cancer usually occurs within 2 years [25-27]. However, only 8 cases of recurrence (40%) among the 20 cases in this study occurred within 2 years, 10 (50%) occurred between 2 years and 5 years, and the remaining 2 occurred after 5 years. The median value of the time to recurrence was 33 months in this study, which was rather different from the results of existing studies (12 to 22 month) [25]. Aghili et al. [28], in a study addressing early and late recurrence of colorectal cancer, reported that 70% of the recurrences in colorectal cancer occurred at an early stage within 2 years and that the factors related to early recurrence were young age, invasion to proximal organs and Duke C stage. The relatively low early recurrence in this study was estimated to be related to the characteristics of the stage I colorectal cancer where invasion to the intestinal wall was limited to the proper muscle.

Hepatic metastasis was reported to be the most common metastasis occurring within two years from the radical resection in studies analyzing the characteristics of recurrence, but after two years, pulmonary metastasis was most commonly seen and was reported as the most common distant metastatic lesion [25]. In this study, one recurrence case from left colon cancer was a hepatic metastasis, and three out of the four cases of pulmonary metastasis from rectal cancer occurred within two years. Six out of the 7 cases of local recurrence from rectal cancer occurred after two years which was distinctive from the existing results showing similar local recurrence rate over the time [25, 28]. Even though a statistically significant comparison was difficult as the size of the sample was small, this recurrence pattern of stage I colorectal cancer is thought to be related to the characteristics of stage I colorectal cancer where invasion is limited to the proper muscle.

Among the 434 patients, 189 underwent postoperative oral immunochemotherapy, but no statistical significance was attached to the way in which the treatment affected the recurrence. However, the conduct of the statistical analysis might have been limited because the surgeons decided on the method and the drug for the therapy by referencing the operation and the pathological finding when they chose the patients for the therapy.

In conclusion, although the recurrence rate of colorectal cancer is around 10%, it is rare for patients to survive longer than 5 years. According to the results in this study, stage I colorectal cancer patients with infiltrative type cancer on the gross finding and with high-grade tumor cell budding were identified as a high risk group, and this should be borne in mind during the follow-up. Moreover, longer follow-up is advised for the high-risk group with rectal cancer, T2 stage and infiltrative type, because, contrary to the recurrence patterns for stage II and III colorectal cancer, more than 60% of the recurrences of stage I colorectal cancer occurred after 2 years.

ARTICLE INFORMATION

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Cancer incidence in Korea 1999-2002. Cancer.go.kr [Internet]. 2008.cited 2011 Aug 1. Goyang: National Cancer Information Cencer, Korea Central Cancer Registry; Available from: http://www.cancer.go.kr/cms/data/edudata/__icsFiles/afieldfile/2009/09/16/aa(aa0606).pdf
2. Park DD, Shin R, Kim JS, Oh HK, Jeong SY, Park KJ, et al. Clinical features of colorectal cancer detected by the national cancer screening program. J Korean Soc Coloproctol 2010;26:420–423. Article PubMed PMC
3. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 2010.7th ed. New York: Springer.
4. Cohen AM, Kelsen D, Saltz L, Minsky BD, Nelson H, Farouk R, et al. Adjuvant therapy for colorectal cancer. Curr Probl Surg 1997;34:601–676. Article PubMed
5. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–358. Article PubMed
6. Stipa S, Nicolanti V, Botti C, Cosimelli M, Mannella E, Stipa F, et al. Local recurrence after curative resection for colorectal cancer: frequency, risk factors and treatment. J Surg Oncol Suppl 1991;2:155–160. Article PubMed
7. Blumberg D, Paty PB, Picon AI, Guillem JG, Klimstra DS, Minsky BD, et al. Stage I rectal cancer: identification of high-risk patients. J Am Coll Surg 1998;186:574–579. Article PubMed
8. Willett CG, Lewandrowski K, Donnelly S, Shellito PC, Convery K, Eliseo R, et al. Are there patients with stage I rectal carcinoma at risk for failure after abdominoperineal resection? Cancer 1992;69:1651–1655. Article PubMed
9. Sticca RP, Rodriguez-Bigas M, Penetrante RB, Petrelli NJ. Curative resection for stage I rectal cancer: natural history, prognostic factors, and recurrence patterns. Cancer Invest 1996;14:491–497. Article PubMed
10. Wichmann MW, Müller C, Hornung HM, Lau-Werner U, Schildberg FW. Colorectal Cancer Study Group. Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World J Surg 2002;26:732–736. Article PubMed
11. Steinberg SM, Barwick KW, Stablein DM. Findings from the Gastrointestinal Tumor Study Group. Importance of tumor pathology and morphology in patients with surgically resected colon cancer. Cancer 1986;58:1340–1345. Article PubMed
12. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115–1122. Article PubMed
13. Michelassi F, Vannucci L, Montag A, Goldberg R, Chappell R, Dytch H, et al. Importance of tumor morphology for the long term prognosis of rectal adenocarcinoma. Am Surg 1988;54:376–379. PubMed
14. Choi PW, Yu CS, Jang SJ, Jung SH, Kim HC, Kim JC. Risk factors for lymph node metastasis in submucosal invasive colorectal cancer. World J Surg 2008;32:2089–2094. Article PubMed
15. Hori H, Fujimori T, Fujii S, Ichikawa K, Ohkura Y, Tomita S, et al. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma. Dis Colon Rectum 2005;48:938–945. Article PubMed
16. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002;45:628–634. Article PubMed
17. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627–635. Article PubMed
18. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127–132. Article PubMed
19. Müller JM, Tübergen D, Zieren U. After-care in colorectal cancer-data and patient oriented evaluation. Zentralbl Chir 1994;119:65–74. PubMed
20. Newland RC, Dent OF, Lyttle MN, Chapuis PH, Bokey EL. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994;73:2076–2082. Article PubMed
21. Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698–702. Article PubMed
22. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 1988;6:119–127. Article PubMed
23. Horn A, Dahl O, Morild I. The role of venous and neural invasion on survival in rectal adenocarcinoma. Dis Colon Rectum 1990;33:598–601. Article PubMed
24. Lim SB, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum 2010;53:377–384. Article PubMed
25. Park IJ, Kim HC, Yu CS, Kim JC. Pattern of recurrences and metastases after a curative resection for primary colorectal cancer. J Korean Soc Coloproctol 2008;24:207–213.Article
26. Griesenberg D, Nürnberg R, Bahlo M, Klapdor R. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 1999;19(4A): 2443–2450. PubMed
27. Steele G Jr. Follow-up plans after treatment of primary colon and rectum cancer. World J Surg 1991;15:583–588. Article PubMed
28. Aghili M, Izadi S, Madani H, Mortazavi H. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol 2010;6:35–41. Article PubMed

Fig. 1

Photomicrography of tumor cell budding. An isolated single cancer cell and a cluster composed of fewer than five cancer cells are identified at the invasive front of the tumor (H&E, × 200).

Table 1

Clinicopathologic characteristics for patients with stage I colorectal cancer (n = 434)

Values are presented as mean (SD) or number (%).

SD, standard deviation; CEA, carcinoembryonic antigen; ICR, ileocecal resection; RHC, right hemicolectomy; LHC, left hemicolectomy; AR; anterior resection; LAR, low anterior resection; ULAR, ultralow anterior resection; APR, abdominoperineal resection; TC, total colectomy; B-I/II, Bormann type-fungating/ulcerofungating; B-III/IV, Bormann type-ulceroinfiltrative/infiltrative; WD, well-differentiated; MD, moderatelydifferentiated; PD, poorly differentiated; SRC, signet ring cell.

Table 2

Clinicopathologic characteristics for patients with recurrence (n = 20)

Table 3

Univariate and multivariate analysis of prognostic factors in stage I colorectal cancer

Values are presented as mean (SD) or number (%).

HR, hazard ratio; CI, confidence interval; SD, standard deviation; CEA, carcinoembryonic antigen; B-I/II, Bormann type-fungating/ulcerofungating; B-III/IV, Bormann type-ulceroinfiltrative/infiltrative; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; SRC, signet ring cell.

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 4

Univariate and multivariate analysis of postoperative oral immunochemotherapy

PICTx, postoperative oral immunochemotherapy; CEA, carcinoembryonic antigen; B-I/II, Bormann type-fungating/ulcerofungating; B-III/IV, Bormann type-ulceroinfiltrative/infiltrative; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; SRC, signet ring cell carcinoma; LVi, lymphovascular invasion.

Regimen of postoperative oral immunochemotherapy: single or combination therapy of oral chemotherapy agent (tegafur/uracil or doxifluridine) and immune modulator (polysaccharide-K) for 3 to 12 months.

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 5

Previous studies for stage I colorectal cancer

LVi, lymphovascular invasion; BVi, blood vessel invasion; CEA, carcinoembryonic antigen.

Figure & Data

References

Citations

Citations to this article as recorded by

Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival
Ewelina Dziąg-Dudek, Aleksandra Semeniuk-Wojtaś, Magdalena Modzelewska, Arkadiusz Lubas, Letycja Róg, Barbara Górnicka, Rafał Stec
Cancers.2026; 18(4): 566. CrossRef
Improving prediction of ypT0–1N0 response in rectal cancer: the added value of gross tumor type to magnetic resonance tumor regression grade after chemoradiotherapy in a retrospective cohort study
Kyong-Min Kang, Mi-Jeong Choi, Hong-min Ahn, Heung-Kwon Oh, Duck-Woo Kim, Jungheum Cho, Won Chang, Young Hoon Kim, Kyoung Ho Lee, Yu Kyung Jun, Yonghoon Choi, Sung-Bum Kang
Annals of Surgical Treatment and Research.2026; 110(4): 237. CrossRef
Tumor budding — independent predictor factor of colorectal cancer
Maxim A. Popov, Sergey A. Savchuk, Demyan P. Kovtun, Gleb N. Khrykov
The Future of Medicine.2026; 1(1): 45. CrossRef
Is tumour location a dominant risk factor of recurrence in early rectal cancer?
Roberto Rosén, Henrik Thorlacius, Carl-Fredrik Rönnow
Surgical Endoscopy.2025; 39(2): 1056. CrossRef
Risk factors for recurrence in stage I colorectal cancer after curative resection: a systematic review and meta-analysis
Sung Hwan Hwang, Seon-Hi Shin, Yun Jin Kim, Jun Ho Lee
Annals of Surgical Treatment and Research.2025; 108(1): 39. CrossRef
Investigation of three alternative histopathological scoring methods at the invasive tumour front in colorectal cancer
Walaiphorn Woraharn, Ashley McCulloch, Christopher Bigley, Phimmada Hatthakarnkul, Kathryn Pennel, Peter Alexander, Hester van Wyk, Antonia Roseweir, Jennifer Hay, Noori Maka, James Park, Nigel B Jamieson, Joanne Edwards, Campbell SD Roxburgh
The Journal of Pathology: Clinical Research.2025;[Epub] CrossRef
Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
Oluwadunni E. Emiloju, Michael Storandt, Tyler Zemla, Nguyen Tran, Krishan Jethwa, Amit Mahipal, Jessica Mitchell, Cornelius Thiels, Kellie Mathis, Robert McWilliams, Joleen Hubbard, Frank Sinicrope, Qian Shi, Zhaohui Jin
JCO Precision Oncology.2024;[Epub] CrossRef
Determinants of survival and recurrence in patients with stage I colorectal cancer
Alimohammad Bananzadeh, Mahshid Bahadori, Mohammad Mohammadianpanah, Faramarz Pakravan, Sara Shojaei-Zarghani, Ali Reza Safarpour
Frontiers in Surgery.2024;[Epub] CrossRef
A systematic review of population‐based studies on metachronous metastases of colorectal cancer
Karin Nyström, Louise Olsson
World Journal of Surgery.2024; 48(6): 1521. CrossRef
Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts
Qingbin Wu, Pengju Chen, Chi Shu, Lin Chen, Zechuan Jin, Jun Huang, Xin Wang, Xue Li, Mingtian Wei, Tinghan Yang, Xiangbing Deng, Aiwen Wu, Yazhou He, Ziqiang Wang
BMC Medicine.2023;[Epub] CrossRef
Risk factors of recurrence in TNM stage I colorectal cancer
Jin-Hee Paik, Chun-Geun Ryu, Dae-Yong Hwang
Annals of Surgical Treatment and Research.2023; 104(5): 281. CrossRef
Postoperative recurrence in locally advanced rectal cancer: how does neoadjuvant treatment affect recurrence pattern?
Ryosuke Okamura, Yoshiro Itatani, Yusuke Fujita, Nobuaki Hoshino, Shintaro Okumura, Kazuhiro Nishiyama, Koya Hida, Kazutaka Obama
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol
Mehraneh D. Jafari, Joseph C. Carmichael, Farshid Dayyani, Chelsea McKinney, Lari Wenzel, Jason A. Zell, Alessio Pigazzi
Clinical Colorectal Cancer.2022; 21(2): 114. CrossRef
The clinic factors in evaluating long-term outcomes of patients with stage I colorectal cancer
Zechuan Jin, Qingbin Wu, Xiangbing Deng, Ziqiang Wang
Asian Journal of Surgery.2022; 45(11): 2231. CrossRef
Identification of high-risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort
Yudai Fukui, Koya Hida, Nobuaki Hoshino, Daisuke Nishizaki, Ryosuke Okamura, Shinichi Yamauchi, Kenichi Sugihara, Yoshiharu Sakai, I. Takemasa, K. Hakamada, H. Kameyama, Y. Takii, H. Ueno, H. Ozawa, S. Ishihara, K. Takahashi, Y. Kanemitsu, M. Itabashi, T.
International Journal of Colorectal Disease.2022; 37(6): 1403. CrossRef
Predicting liver metastases growth patterns: Current status and future possibilities
Rui Caetano Oliveira, Henrique Alexandrino, Maria Augusta Cipriano, Filipe Caseiro Alves, José Guilherme Tralhão
Seminars in Cancer Biology.2021; 71: 42. CrossRef
Improved Outcomes and Staging in Non-Small-Cell Lung Cancer Guided by A Molecular Assay
Alexander R Gupta, Gavitt A Woodard, David M Jablons, Michael J Mann, Johannes R Kratz
Future Oncology.2021; 17(34): 4785. CrossRef
Tumor Size >5 cm and Harvested LNs <12 Are the Risk Factors for Recurrence in Stage I Colon and Rectal Cancer after Radical Resection
Hye-Sol Jung, Seung-Bum Ryoo, Han-Ki Lim, Min Jung Kim, Sang Hui Moon, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park
Cancers.2021; 13(21): 5294. CrossRef
High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer
Andreas H Marx, Claudius Mickler, Guido Sauter, Ronald Simon, Luigi M Terracciano, Jakob R Izbicki, Till S Clauditz
International Journal of Colorectal Disease.2020; 35(2): 259. CrossRef
Factors influencing recurrence of stage I–III rectal cancer in regional Australia
Lucy Haggstrom, Sharlyn Kang, Robert Winn, Soni Putnis, Elias Nasser, James Chen, Morteza Aghmesheh, Daniel Brungs
ANZ Journal of Surgery.2020; 90(12): 2490. CrossRef
Pathological risk factors and predictive endoscopic factors for lymph node metastasis of T1 colorectal cancer: a single-center study of 846 lesions
Chihiro Yasue, Akiko Chino, Manabu Takamatsu, Ken Namikawa, Daisuke Ide, Shoichi Saito, Masahiro Igarashi, Junko Fujisaki
Journal of Gastroenterology.2019; 54(8): 708. CrossRef
Influence of gross tumor morphology on clinicopathological profile of colorectal cancers
Mudassir Ahmad Khan, Nisar A. Chowdri, Showkat Ali Bhat, Fazl Q. Parray, Rauf A. Wani, Asif Mehraj
Current Medicine Research and Practice.2019; 9(5): 172. CrossRef
Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection
Chan Kim, Woo Ram Kim, Ki-Yeol Kim, Hong Jae Chon, Seung Hoon Beom, Hyojoong Kim, Minkyu Jung, Sang Joon Shin, Nam Kyu Kim, Joong Bae Ahn
Clinical Colorectal Cancer.2018; 17(3): e513. CrossRef
Emergency resection surgery for colorectal cancer: Patterns of recurrent disease and survival
Joe Littlechild, Muneer Junejo, Anne-Marie Simons, Finlay Curran, Darren Subar
World Journal of Gastrointestinal Pathophysiology.2018; 9(1): 8. CrossRef
Identification of Recurrence—Predictive Indicators in Stage I Colorectal Cancer
Jun Ho Lee, Jong Lyul Lee, In Ja Park, Seok‐Byung Lim, Chang Sik Yu, Jin Cheon Kim
World Journal of Surgery.2017; 41(4): 1126. CrossRef
Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016
Alessandro Lugli, Richard Kirsch, Yoichi Ajioka, Fred Bosman, Gieri Cathomas, Heather Dawson, Hala El Zimaity, Jean-François Fléjou, Tine Plato Hansen, Arndt Hartmann, Sanjay Kakar, Cord Langner, Iris Nagtegaal, Giacomo Puppa, Robert Riddell, Ari Ristimäk
Modern Pathology.2017; 30(9): 1299. CrossRef
Tumor budding in colorectal cancer—ready for diagnostic practice?
Viktor H. Koelzer, Inti Zlobec, Alessandro Lugli
Human Pathology.2016; 47(1): 4. CrossRef
Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis
Sun A Kim, Kentaro Inamura, Mai Yamauchi, Reiko Nishihara, Kosuke Mima, Yasutaka Sukawa, Tingting Li, Mika Yasunari, Teppei Morikawa, Kathryn C Fitzgerald, Charles S Fuchs, Kana Wu, Andrew T Chan, Xuehong Zhang, Shuji Ogino, Zhi Rong Qian
British Journal of Cancer.2016; 114(2): 199. CrossRef
Recurrence in patients with stage I colorectal cancer
Patrick Ely Teloken, David Ransom, Ian Faragher, Ian Jones, Peter Gibbs, Cameron Platell
ANZ Journal of Surgery.2016; 86(1-2): 49. CrossRef
Preoperative Carcinoembryonic Antigen and Prognosis of Colorectal Cancer. An Independent Prognostic Factor Still Reliable
Giovanni Li Destri, Antonio Salvatore Rubino, Rosalia Latino, Fabio Giannone, Raffaele Lanteri, Beniamino Scilletta, Antonio Di Cataldo
International Surgery.2015; 100(4): 617. CrossRef
Factors affecting sphincter-preserving resection treatment for patients with low rectal cancer
ZHENQIANG SUN, XIANBO YU, HAIJIANG WANG, MING MA, ZELIANG ZHAO, QISAN WANG
Experimental and Therapeutic Medicine.2015; 10(2): 484. CrossRef
Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin
Eva Karamitopoulou, Inti Zlobec, Viktor Hendrik Koelzer, Rupert Langer, Heather Dawson, Alessandro Lugli
Histopathology.2015; 67(4): 464. CrossRef
Tumor budding in the clinical management of colon and rectal cancer
Viktor H Koelzer, Inti Zlobec, Alessandro Lugli
Colorectal Cancer.2014; 3(4): 387. CrossRef
Clinical Management of Localized Colon Cancer with Capecitabine
J. Quidde, D. Arnold, A. Stein
Clinical Medicine Insights: Oncology.2012;[Epub] CrossRef
Early Detection of Colorectal Cancer, Is It a Guarantee for the Cure of Cancer?
Kang Young Lee
Journal of the Korean Society of Coloproctology.2012; 28(1): 6. CrossRef

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinicopathologic Factors Affecting Recurrence after Curative Surgery for Stage I Colorectal Cancer

J Korean Soc Coloproctol. 2012;28(1):49-55. Published online February 29, 2012

DOI: https://doi.org/10.3393/jksc.2012.28.1.49

XML Download

Figure

Related articles

Clinicopathologic Factors Affecting Recurrence after Curative Surgery for Stage I Colorectal Cancer

Fig. 1 Photomicrography of tumor cell budding. An isolated single cancer cell and a cluster composed of fewer than five cancer cells are identified at the invasive front of the tumor (H&E, × 200).

Fig. 1

Clinicopathologic Factors Affecting Recurrence after Curative Surgery for Stage I Colorectal Cancer

Table 1

Clinicopathologic characteristics for patients with stage I colorectal cancer (n = 434)

Values are presented as mean (SD) or number (%).

Table 2

Clinicopathologic characteristics for patients with recurrence (n = 20)

Table 3

Univariate and multivariate analysis of prognostic factors in stage I colorectal cancer

Values are presented as mean (SD) or number (%).

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 4

Univariate and multivariate analysis of postoperative oral immunochemotherapy

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 5

Previous studies for stage I colorectal cancer

LVi, lymphovascular invasion; BVi, blood vessel invasion; CEA, carcinoembryonic antigen.

Table 1 Clinicopathologic characteristics for patients with stage I colorectal cancer (n = 434)

Values are presented as mean (SD) or number (%).

Table 2 Clinicopathologic characteristics for patients with recurrence (n = 20)

Table 3 Univariate and multivariate analysis of prognostic factors in stage I colorectal cancer

Values are presented as mean (SD) or number (%).

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 4 Univariate and multivariate analysis of postoperative oral immunochemotherapy

Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.

Table 5 Previous studies for stage I colorectal cancer

LVi, lymphovascular invasion; BVi, blood vessel invasion; CEA, carcinoembryonic antigen.